Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

25.79
+0.31001.22%
Post-market: 25.30-0.4800-1.86%19:59 EDT
Volume:4.25M
Turnover:111.34M
Market Cap:2.89B
PE:-25.57
High:26.95
Open:26.09
Low:25.70
Close:25.48
Loading ...

Viking Therapeutics (VKTX): Among the Oversold Biotech Stocks to Buy Now

Insider Monkey
·
25 Feb

Should You Buy VKTX Stock Amid Renewed M&A Speculations?

Zacks
·
24 Feb

Citi Reaffirms Their Hold Rating on Viking Therapeutics (VKTX)

TIPRANKS
·
24 Feb

Truist Financial Remains a Buy on Viking Therapeutics (VKTX)

TIPRANKS
·
24 Feb

Why Viking Therapeutics Inc. (VKTX) Surged On Friday?

Insider Monkey
·
22 Feb

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
22 Feb

Viking Therapeutics rumor highlighted in Betaville alert

TIPRANKS
·
22 Feb

Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

Insider Monkey
·
20 Feb

LLY Rises More Than 4% in a Week: How to Play the Stock

Zacks
·
13 Feb

Scotiabank Initiates Viking Therapeutics at Sector Outperform

MT Newswires Live
·
13 Feb

Viking Therapeutics Inc : Scotiabank Initiates Coverage With Sector Outperform Rating; Target Price $102

THOMSON REUTERS
·
13 Feb

Viking Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
13 Feb

Why Viking Therapeutics Inc. (VKTX) Went Down on Monday

Insider Monkey
·
11 Feb

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Motley Fool
·
11 Feb

The M&A Boom Of 2025 Is Just Getting Started - And Here Are 5 Potential Targets

Dow Jones
·
09 Feb

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

TipRanks
·
08 Feb

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

Motley Fool
·
08 Feb

Viking Therapeutics price target lowered to $95 from $120 at Truist

TIPRANKS
·
08 Feb

Truist Securities Adjusts Viking Therapeutics Price Target to $95 From $120, Maintains Buy Rating

MT Newswires Live
·
07 Feb

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb